Patent: 10,023,894

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $100
Remove trial restrictions

Summary for Patent: 10,023,894

Title:	Galactose-alpha-1, 3-galactose-containing n-glycans in glycoprotein products derived from CHO cells
Abstract:	Methods of producing recombinant therapeutic fusion proteins described herein can include culturing Chinese hamster ovary (CHO) cells under conditions suitable for expression of a recombinant therapeutic fusion protein including one or more glycans, where the CHO cells have not been genetically engineered to produce terminal alpha-galactosyl residues on glycans; treating the one or more glycans of the recombinant glycoprotein with one or more exoglycosidases; measuring glycans containing terminal galactose-alpha-1-3-galactose residues on the fusion protein by nuclear magnetic resonance (NMR); and producing a recombinant therapeutic fusion protein in the CHO cells if a target level of terminal galactose-alpha-1-3-galactose residues is measured.
Inventor(s):	Bosques; Carlos J. (Arlington, MA), Murphy; Jennifer (Marshfield, MA), Sarvaiya; Hetal (Quincy, MA), Washburn; Nathaniel (Littleton, MA), Liu; Cuihua (Belmont, MA), Xu; Xiao-Jin (Southborough, MA)
Assignee:	Momenta Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	14/832,784
Patent Claims:	see list of patent claims

Details for Patent 10,023,894

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	12/23/2005	⤷ Sign Up	2029-01-22
Bristol-myers Squibb Company	ORENCIA	abatacept	Injection	125118	07/29/2011	⤷ Sign Up	2029-01-22
Bristol-myers Squibb Company	ORENCIA	abatacept	Injection	125118	06/07/2016	⤷ Sign Up	2029-01-22
Bristol-myers Squibb Company	ORENCIA	abatacept	Injection	125118	03/30/2017	⤷ Sign Up	2029-01-22
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.